 The Star-Ledger - NJ.com | Bristol-Myers suspends hepatitis C treatment study, cites patient safety problem Washington Post NEW YORK â€" Drugmaker Bristol-Myers Squibb Co. is suspending a midstage study of a potential hepatitis C treatment because of a serious patient safety issue. The New York company did not elaborate on the problem in a brief statement released ... Bristol-Myers exec charged with insider trading Bristol-Myers Executive Ramnarine Charged With Insider Trading Bristol-Myers Squibb exec arrested for insider trading |
Thursday, August 2, 2012
Bristol-Myers suspends hepatitis C treatment study, cites patient safety problem - Washington Post
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment